BIOA

BioAge Labs, Inc.

Fundamental data last updated:August 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.

 


Analyze BIOA on TradingView

VALUATION

P/E

-8.05

Market Cap ($M USD)

$641.93M

Forward P/E

-5.92

PEG

0.16

PRICE TO SALES

62.23

PRICE TO BOOK

1.91

EV / EBITDA

-4.38

5-Year Average P/E

Free Cash Flow Yield

-13.81%

DCF Value

$9.07

Graham Number

N/A

Price to FCF

-7.24

EV to FCF

-4.56

Earnings Yield

-12.42%

FCF Yield

-13.81%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$2.12

Next Year EPS Growth Estimate

-$2.88

Next Year Revenue Growth Estimate

$64.59M

Return on Equity (ROE)

-29.40%

FREE CASH FLOW

Operating Margin

-985.93%

Debt-to-Equity

0.02

Piotroski F-Score

3

Altman Z-Score

18.89

Return on Invested Capital (ROIC)

-26.64%

Current Ratio

24.76

Quick Ratio

24.76

Net Debt to EBITDA

2.57

Interest Coverage

-211.45

Gross Profit margin

99.39%

FCF PER SHARE

$-2.09

REVENUE PER SHARE

$0.24

Analyze BIOA on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing BioAge Labs, Inc. significantly. Despite a DCF value below the recent pricing, the Forward P/E and Earnings Yield paint a grim picture of profitability. The Altman Z-score, however, suggests financial stability, indicating the company isn’t on the brink of distress. Yet, with a negative earnings yield and a PEG ratio that screams undervaluation, the market might be underestimating its future growth potential. This is a classic case of high risk, high reward, where the valuation metrics are at odds with each other.

AI Exposure / Tech Reliance

In the biotechnology sector, BioAge Labs is well-positioned to leverage AI and tech advancements. The industry inherently benefits from AI-driven drug discovery and personalized medicine. This alignment with cutting-edge technology could enhance their research efficiency and innovation pipeline.

The Bull Case

For the value or GARP investor, BioAge Labs presents a compelling opportunity. The low PEG ratio suggests significant growth potential at a bargain price. Despite a negative FCF Yield, the company's high ROIC indicates efficient capital use. The Piotroski F-Score is modest, but the impressive gross profit margin hints at strong pricing power, suggesting management's ability to convert revenue into profit effectively.

The Bear Case

BioAge Labs faces daunting structural risks. The Price/Sales ratio is alarmingly high, indicating the stock may be overvalued relative to its revenue. The negative operating margin and EPS highlight severe profitability issues. Despite a low Debt/Equity ratio, the company's cash flow struggles, as evidenced by the negative FCF Yield and Price to FCF, raise concerns about its ability to sustain operations without external financing.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$42.20

Institutional Ownership %

1-Year Beta

1.00

Insider Buying % (6 Mo)

Distance to 52-Week High

40.76%

Distance to 52-Week Low

77.24%

EARNINGS SURPRISE %

18.70%

50-DAY SMA

$17.44

200-DAY SMA

$13.04

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.